Platelet activating factor
Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
Cross Reference
Introduction
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Platelet activating factor?
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
PubChem Associated disorders and diseases
What pathways are associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Platelet activating factor?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Platelet activating factor?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Platelet activating factor?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Platelet activating factor?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Platelet activating factor?
Knock-out
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Platelet activating factor
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Hirt SW et al. | Antagonisation of platelet activating factor--a new therapeutic concept for improvement of organ quality in lung preservation. | 1992 | Transpl. Int. | pmid:14621825 |
| Torras J et al. | Protective effect of the PAF antagonist BN 52021 in an experimental renal warm ischemia model. | 1993 | Transpl. Int. | pmid:8347271 |
| Räisänen A et al. | Effect of platelet-activating factor (PAF) receptor blockers on smooth muscle cell replication in vitro and allograft arteriosclerosis in vivo. | 1993 | Transpl. Int. | pmid:8216700 |
| Wang KS et al. | Protective effects of a PAF antagonist against liver injury induced by warm ischemia or cold preservation. | 1992 | Transplant. Proc. | pmid:1496669 |
| Takada Y et al. | Improvement of allograft viability with organs procured from non-heart-beating donors in porcine liver transplantation. | 2000 | Transplant. Proc. | pmid:10715416 |
| Fukuoka T et al. | Platelet activating factor mediates systemic circulatory collapse after temporary hepatic inflow occlusion. | 1993 | Transplant. Proc. | pmid:8470175 |
| Peyman JA et al. | HLA-DR genes are silenced in human trophoblasts and stimulation of signal transduction pathways does not circumvent interferon-gamma unresponsiveness. | 1992 | Transplant. Proc. | pmid:1533073 |
| Taniguchi S et al. | Effects of a platelet-activating factor antagonist at different doses given simultaneously with double-filtration plasmapheresis on cardiac xenograft survival. | 1994 | Transplant. Proc. | pmid:8171719 |
| Coughlan AF et al. | In vivo studies of P-selectin and platelet activating factor during endotoxemia, accelerated allograft rejection, and discordant xenograft rejection. | 1993 | Transplant. Proc. | pmid:7692651 |
| Hammer C et al. | Xenogeneic rejection mechanisms shown by intravital microscopy. | 1998 | Transplant. Proc. | pmid:9865335 |
| Takada Y et al. | Energy metabolism of hepatic allografts subjected to prolonged warm ischemia and pharmacologic modulation with FK506 and platelet activating factor antagonist. | 1998 | Transplant. Proc. | pmid:9838621 |
| Fukunaga K et al. | Successful liver transplantation from non-heart-beating donors by blockade of endothelin and PAE. | 1998 | Transplant. Proc. | pmid:9838664 |
| Lloberas N et al. | The ether phospholipids trail: blood timing in renal ischemia-reperfusion injury. | 2002 | Transplant. Proc. | pmid:11959179 |
| Castellvi J et al. | Effect of the platelet-activating factor antagonist BN-52021 on liver preservation (4 degrees): experimental study in isolated reperfused rat liver model. | 2002 | Transplant. Proc. | pmid:11959181 |
| Metcalfe SM et al. | Survival of renal allografted dogs after limited therapy with cyclosporine and the PAF antagonist WEB 2170. | 1991 | Transplant. Proc. | pmid:1871852 |
| Pirotzky E et al. | Cyclosporine-induced nephrotoxicity: preventive effect of a PAF-acether antagonist, BN 52063. | 1988 | Transplant. Proc. | pmid:3388505 |
| Keskinoglu A et al. | Inflammatory lipid mediators and immunologic recognition in allogeneic renal transplantation. | 1997 Feb-Mar | Transplant. Proc. | pmid:9122948 |
| Otte KE et al. | Xenoperfusion of rabbit kidney and the impact of BN 52021: a specific antagonist of platelet-activating factor. | 1990 | Transplant. Proc. | pmid:2349668 |
| Moreno P et al. | Changes in peripheral blood levels of platelet-activating factor after orthotopic liver transplantation. | 1993 | Transplant. Proc. | pmid:8395105 |
| Kecskemeti V and Balogh I | Cardiac electrophysiologic and ultrastructural effects of platelet-activating factor and its antagonist BN 52021. | 1995 | Transplant. Proc. | pmid:7482928 |
| Yin M et al. | Platelet-activating factor antagonist TCV-309 protects rat kidneys against ischemia-reperfusion injury. | 1995 | Transplant. Proc. | pmid:7482939 |
| Spiegel HU et al. | Beneficial effect of the platelet-activating factor antagonist WEB 2170 on reperfusion injury after orthotopic liver transplantation. | 1995 | Transplant. Proc. | pmid:7482955 |
| Foegh ML | Eicosanoids and platelet activating factor mechanisms in organ rejection. | 1988 | Transplant. Proc. | pmid:3059615 |
| Mahmoud FF et al. | In vitro effects of ginkgolide B combined with cyclosporin A on T-lymphocyte activation and IL-5 expression in peripheral blood mononuclear cells from asthmatic subjects. | 2002 | Transplant. Proc. | pmid:12431672 |
| Borobia FG et al. | Platelet-activating factor antagonist BN52021 improves survival in normothermic liver ischemia in rats. | 1993 | Transplant. Proc. | pmid:8356661 |
| Toledo-Pereyra LH and Suzuki S | Cellular and biomolecular mechanisms of liver ischemia and reperfusion injury. | 1994 | Transplant. Proc. | pmid:8109001 |
| Iwamoto H et al. | Beneficial effect of machine perfusion preservation on liver transplantation from non-heart-beating donors. | 2000 | Transplant. Proc. | pmid:11119873 |
| Da Costa M et al. | Prolongation of rat heart allograft survival using low-dose cyclosporine and PAF antagonist WEB 2170. | 1990 | Transplant. Proc. | pmid:2389490 |
| Bergmann R et al. | Effects of a PAF-antagonist (WEB 2086) on hyperacute xenogeneic rejection in ex vivo perfused kidneys. | 1990 | Transplant. Proc. | pmid:2389511 |
| Immunomodulation: other approaches. | 1988 | Transplant. Proc. | pmid:3347955 | |
| Renkonen R et al. | Second messenger pathways in lymphocyte binding and penetration through graft vascular endothelium. | 1991 | Transplant. Proc. | pmid:1846709 |
| O'Hair DP et al. | Platelet activating factor antagonist RP-59227 reduces vascular injury in discordant cardiac xenograft rejection. | 1992 | Transplant. Proc. | pmid:1566490 |
| Pignol B et al. | Potentiation of immunosuppressive action of cyclosporine A by platelet-activating factor antagonists: an approach of the mechanism of action of these drugs in the prevention of graft rejection. | 1988 | Transplant. Proc. | pmid:3259039 |
| Miyatake T et al. | Analysis of cardiac function during hyperacute rejection: effects of PAF antagonist, TXA(2) inhibitor/antagonists, and nitroglycerin. | 2000 | Transplant. Proc. | pmid:10936319 |
| First International Alexis Carrel Conference on Lipid Mediators in Organ Transplantation. April 8-10, 1986, Washington, DC. | 1986 | Transplant. Proc. | pmid:3765055 | |
| Minor T et al. | Treatment of preservation/reperfusion injury by platelet-activating factor antagonism in the rat liver graft. | 1995 | Transplant. Proc. | pmid:7879086 |
| Ide S et al. | Donor administration of PAF antagonist (TCV-309) enhances lung preservation. | 1995 | Transplant. Proc. | pmid:7879103 |
| Takada Y et al. | Platelet activating factor antagonist has a protective effect on preservation/reperfusion injury of the graft in pig liver transplantation. | 1995 | Transplant. Proc. | pmid:7879169 |
| Yin M et al. | Beneficial effect of platelet-activating factor antagonist TCV-309 on renal ischemia-reperfusion injury. | 1995 | Transplant. Proc. | pmid:7879180 |
| Chávez-Cartaya RE et al. | Rat liver blood flow after ischemia and reperfusion. The effects of the platelet-activating factor antagonist WEB-2170 and of removing circulating leukocytes. | 1994 | Transplantation | pmid:8197604 |
| Pi F et al. | Effect of a platelet-activating factor antagonist and desferrioxamine administration on eicosanoid production in rat pancreas transplantation. | 1994 | Transplantation | pmid:8291097 |
| Lanese DM et al. | Sequential agonist activation and site-specific mediation of acute cyclosporine constriction in rat renal arterioles. | 1994 | Transplantation | pmid:7809931 |
| dos Santos OF et al. | Effect of platelet-activating factor antagonist on cyclosporine nephrotoxicity. Glomerular hemodynamics evaluation. | 1989 | Transplantation | pmid:2705209 |
| Saumweber DM et al. | Hyperacute rejection in an ex vivo model of renal xenografting. Role of the mediator response and its pharmacologic manipulation by the specific platelet-activating factor antagonist WEB 2086BS. | 1994 | Transplantation | pmid:8108870 |
| Camussi G et al. | Release of platelet-activating factor from rabbit heart perfused in vitro by sera with transplantation alloantibodies. | 1987 | Transplantation | pmid:3299910 |
| Yin M et al. | The PAF antagonist TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia. | 1996 | Transplantation | pmid:8633367 |
| Nishiyama R et al. | Platelet-activating factor in hepatic ischemia/reperfusion injury. The effects of a PAF antagonist combined with a prostaglandin I2 analogue. | 1993 | Transplantation | pmid:8516812 |
| Kawahara K et al. | The effect of the platelet-activating factor inhibitor TCV-309 on reperfusion injury in a canine model of ischemic lung. | 1993 | Transplantation | pmid:8516834 |
| Takada Y et al. | Effects of platelet-activating factor antagonist on preservation/reperfusion injury of the graft in porcine orthotopic liver transplantation. | 1995 | Transplantation | pmid:7839408 |
| Suzuki S et al. | The roles of platelet-activating factor and endothelin-1 in renal damage after total hepatic ischemia and reperfusion. | 2000 | Transplantation | pmid:10868624 |